Developer docs
API playgroundTry for free, no card

Search company profiles

Nbryo

Full company profile

uuid0005kam

Namestring
Nbryo
Legal namestring
Nbryo Pty Limited
Websiteurl
nbryo.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Nbryo is an Australian agri-biotech company developing and commercialising an integrated platform for scalable bovine in vitro fertilisation (IVF) and embryo transfer, aimed at cattle seedstock producers, commercial beef operations, and dairy farmers. Founded from 15 years of embryo transfer and genomics research at the Nindooinbah breeding property in Queensland, the company opened its first state-of-the-art Bovine IVF laboratory and headquarters in Eight Mile Plains, Brisbane in October 2023, and has since established two purpose-built Donor Centres in Toogoolawah and Dalby for producers with fewer than 25 donors. The platform combines four integrated steps: genetic selection (including sexing and genomic pre-implantation screening), embryo production via proprietary in vitro production (IVP) culture plus the patented embryo multiplication technology launched in November 2025, a simplified embryo transfer device targeted for October 2026 release, and an AI/ML analytics layer for supply chain forecasting and traceability. Its headline technical claim is condensing seven years of conventional genetic improvement into a seven-day IVP cycle, with multiplication technology delivering twice the embryos using half the donors and half the semen.

The business model combines fee-for-service revenue (OPU, embryo production, fresh and frozen embryo transfer delivered on-farm or via Donor Centres) with unit-priced embryo sales at an introductory AUD $150 per Grade 1 embryo, reduced from AUD $180 following multiplication Stage 1. Go-to-market is sales-led and direct, supported by an in-house field services team, a Tech Ambassador Program of early-adopter reference customers, and an industry partnership with the Australian Wagyu Association. Marketing channels include the proprietary 'Leading the Herd' podcast, an extensive knowledge base, agricultural media coverage, and field-day events. Revenue is not publicly disclosed.

The company is privately held and venture-backed, having raised over AUD $22 million in equity since 2024 across a $10M first close (October 2025) and an $8M second close (March 2026 anchored by USD $4M from the Gates Foundation), plus over AUD $18 million in grant funding from the Gates Foundation, Meat & Livestock Australia, and Australian state and federal programs. Key equity investors include Tenacious Ventures, AgriZeroNZ, Queensland Investment Corporation, Mandalay Venture Partners, and the Murdoch family. Leadership comprises CEO Paul Niven (appointed January 2025), Executive Chairman Dr Gerard Davis, and Co-Founders Euan Murdoch and Nick Cameron, supported by a team of approximately 20 spanning embryology, research, operations, and commercial functions.

Short descriptiontext

Nbryo is an Australian agri-biotech company commercialising an integrated bovine IVF and embryo transfer platform that enables accelerated, affordable genetic improvement for seedstock, commercial beef, and dairy producers through patented embryo multiplication and bio-digital technologies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEight Mile Plains, Australia
HQ citystring
Eight Mile Plains
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bovine IVF services, embryo transfer technology, livestock genetic improvement, cattle breeding biotechnology, animal reproductive services
Industry2 codes
PRIMARYAFACAEAB
Embryo Transfer (ET) & IVF Services (Superovulation, Flushing, Implantation)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Livestock Services (Breeding, AI, Pregnancy Checking, Handling)
SECONDARYAFACAEAD
Breeding Program Design & Genetic Consulting (Mating Plans, EPD/Index Selection)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Livestock Services (Breeding, AI, Pregnancy Checking, Handling)
NAICS code1 code
  • Support Activities for Animal Production11521
SIC code2 codes
  • Agricultural Services700
  • Services-Commercial Physical & Biological Research8731
Product category
Livestock Reproductive Biotechnology Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1IVF and Embryo Transfer Services
TypeProfessional Services
Description

Nbryo provides commercial in vitro fertilisation (IVF) and embryo transfer (ET) services to cattle producers. Oocyte collection (OPU), embryo production, fresh or frozen embryo transfer, and associated laboratory services are offered as fee-for-service programs. Services are delivered on-farm or at Nbryo's Donor Centres.

nbryo.com
2Embryo Sales (Grade 1 Embryos)
TypeOne Time License
Description

Nbryo produces and sells Grade 1 embryos at AUD $150 (introductory price, reduced from $180). Embryo multiplication technology enables higher embryo yields, reducing cost per embryo. Future genomic screening will allow selection of embryos with specific traits before transfer.

nbryo.com
3Equity Capital Raising
TypeLicensing Royalties
Description

Nbryo has raised over AUD $22 million in equity since 2024, including a $10 million first close (October 2025) and an $8 million second close (March 2026). The Gates Foundation contributed USD $4 million. SAFE note conversion of $12.3 million brought total raised since 2024 to over $22 million. Additionally, over $18 million in grant funding has been received from Gates Foundation, Meat & Livestock Australia, and government programs.

nbryo.com
4Equity Investment (Seed Round)
TypeLicensing Royalties
Description

Nbryo has an open Seed Round for new equity investors, managed by Investor Relations contact Nick Bonifant. The company is raising capital to fund technology development, commercial expansion, and the October 2026 product launch.

nbryo.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details4 tiers
1Grade 1 Embryo — Introductory Price
ModelUnit PricingBilling cadencePay-as-you-go
Notes

AUD $150 per Grade 1 embryo (introductory price, reduced from AUD $180). Price reduction enabled by embryo multiplication technology Stage 1. Further reductions expected as the platform scales.

nbryo.com
2Donor Centre IVF Programs
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Donor Centre model designed for producers with fewer than 25 donors. Provides structured, donor-focused IVF programs integrating OPU, fertilisation, embryo culture and transfer planning. Cost-effective for smaller producers who cannot achieve economies of scale with on-farm infrastructure.

nbryo.com
3Oocyte Collection (OPU) Services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

On-farm or at-collection-centre ovum pick-up (OPU) services performed by Nbryo's experienced field services team. OPU can be performed as frequently as fortnightly. Optional FSH stimulation available to increase oocyte quality and EDR.

nbryo.com
4Embryo Transfer Services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Fresh or frozen embryo transfer services by experienced field team. Fixed-time embryo transfer (FTET) protocols available. Embryo transfer device (October 2026 launch) designed to reduce need for specialist ET vet, lowering cost barrier.

nbryo.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nbryo provides commercial bovine in vitro fertilisation (IVF), ovum pick-up (OPU), and embryo transfer (ET) services to cattle producers, producing and selling Grade 1 embryos at AUD $150 per unit. The offering is anchored by a patented Embryo Multiplication Technology that doubles embryo yield while improving Embryo Development Rates, and is delivered through on-farm field services, two purpose-built Donor Centres in Queensland, and a development pipeline that includes genomic pre-implantation screening, a proprietary embryo transfer device, and AI/ML-enabled herd analytics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 7 years of genetic improvement achievable in a 7-day in vitro embryo production cycle, compared to existing systems that achieve 10% trait improvement over 7 years at best
+5 more records
Product overview1 text field

Nbryo is developing and commercialising an integrated technology platform for bovine IVF that enables accessible, accelerated, and affordable genetic improvement through in vitro production of embryos. The platform combines eight key services across the reproductive technology workflow: Breeding Objective Design (in development), Oocyte Collection Services, Embryo Production, Genomic Screening (coming soon), Embryo Multiplication Technology (launched November 2025), Embryo Preservation (in development), Embryo Transfer Technology with a device planned for October 2026 release, and Analysis/Data Services. Using advanced bio-digital and robotic technologies, the platform enables 7 years of genetic improvement to be achieved within a 7-day in vitro embryo production cycle. Nbryo also operates Donor Centre facilities in Toogoolawah and Dalby, Queensland.

Product and service6 records
1Commercial IVF and Embryo Transfer Services
CategoryReproductive services
Description

Fee-for-service commercial bovine IVF program delivered through Nbryo's field services team and laboratory. Includes ovum pick-up (OPU) on-farm or at collection centres, fertilisation and embryo culture in the lab, and fresh or frozen embryo transfer using fixed-time embryo transfer (FTET) protocols. Optional FSH stimulation is available to increase oocyte quality and Embryo Development Rates. OPU can be performed as frequently as fortnightly. Services are delivered on-farm for larger producers and via Donor Centres for those with fewer than 25 donors.

2Nbryo Donor Centres
CategoryFacility-based reproductive services
Description

Two purpose-built facilities in Toogoolawah and Dalby, Queensland, that provide structured, donor-focused IVF programs integrating donor management, OPU, fertilisation, embryo culture, and transfer planning. Designed for producers with fewer than 25 donors who cannot achieve economies of scale with on-farm infrastructure, making advanced reproductive technology accessible, practical, and affordable.

3Embryo Multiplication Technology
CategoryProprietary biotechnology platform
Description

A patented biological process that naturally multiplies embryo yield while improving Embryo Development Rates. Not cloning or embryo splitting, the technology produces more Grade 1 embryos at lower cost. Enabled Grade 1 embryo introductory pricing of AUD $150 (reduced from AUD $180), with further cost reductions expected as the platform scales.

4Embryo Transfer Device
CategoryProprietary device
Description

A proprietary device under development that will enable semi-skilled operators such as AI technicians to perform embryo transfers into recipient cows without requiring a specialist ET vet or epidural. Designed to lower skill barriers, reduce cost, and address the critical shortage of skilled embryo transfer technicians in the cattle industry.

5Genomic Pre-implantation Screening
CategoryGenomic screening service
Description

Technology to select or de-select embryos in the dish based on genomic traits including gender, horn/poll status, recessive genetic conditions, coat colour, and performance-oriented SNP panels. Enables selection of embryos before implantation rather than waiting for calf birth to assess traits, supporting faster structural herd change and direct selection for methane reduction, productivity, and welfare traits.

6Grade 1 Embryos
CategoryBiological product
Description

Nbryo produces and sells Grade 1 embryos at an introductory price of AUD $150 per embryo, reduced from AUD $180 through Stage 1 of embryo multiplication technology. Embryo multiplication enables higher yields and lower per-embryo cost. Future genomic screening will allow selection of embryos with specific traits before transfer.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Australian Wagyu Association (AWA)
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Corporate business partnership recognising alignment between Nbryo and AWA in advancing the Australian livestock industry. Partnership provides market access and co-marketing opportunities within the Australian Wagyu breeder community. AWA members benefit from preferential access to Nbryo's IVF services and technology platform.

nbryo.com
Strategic tierResearchTypeStrategic or Co-development Partner
Description

Research partner contributing scientific expertise. Associate Professor Margot Day serves as Nbryo's Lead Scientist from the University of Sydney, playing a key role in developing the embryo multiplication technology.

Strategic tierResearchTypeStrategic or Co-development Partner
Description

Research partner from the Nbryo/Nindooinbah program origins. Euan Murdoch served as Adjunct Professor at UQ's Australian Institute of Bioengineering and Nanotechnology and member of UQ's Institute of Molecular Biosciences Commercialisation Board.

Strategic tierResearchTypeStrategic or Co-development Partner
Description

Research partner in Nbryo's multi-disciplinary product development network spanning biology, genomics, engineering, biosensors, and data science. Research partner Crispin from RMIT is referenced in team activities.

Strategic tierResearchTypeStrategic or Co-development Partner
Description

International research partner in Nbryo's network across Australia, New Zealand, India, Kenya, and the USA.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

ILRI Director General Professor Appolinaire Djikeng serves on Nbryo's Scientific Advisory Committee. ILRI focuses on challenges facing smallholder production systems in Sub-Saharan Africa, where Nbryo plans to deploy its platform to address food security and climate challenges. Collaboration helps plan Nbryo platform development for developing country contexts.

7Jemalong Pastoral Company
Strategic tierPilotTypeGTM or Marketing Partner
Description

Queensland Wagyu operation participating in Nbryo's Tech Ambassador Program as an early adopter of Nbryo's IVF technology. The Bachmann family (Maree and Russell) completed two OPU sessions producing 62 embryos implanted into recipients. They serve as reference customers and advocates, providing feedback on early-stage technology.

nbryo.com
Strategic tierResearchTypeTechnology or Integration
Description

Partner company in Nbryo's research network contributing to platform development.

9Expedite Animal Health
Strategic tierResearchTypeTechnology or Integration
Description

Partner company in Nbryo's research network contributing to the development of reproductive biotechnology.

nbryo.com
Strategic tierResearchTypeStrategic or Co-development Partner
Description

Partner institution in Nbryo's international research network contributing to platform development for livestock genetic improvement.

Strategic tierResearchTypeStrategic or Co-development Partner
Description

Partner organisation in Nbryo's research network with focus on agricultural greenhouse gas mitigation, directly aligned with Nbryo's methane reduction technology goals.

Strategic tierResearchTypeTechnology or Integration
Description

Partner company in Nbryo's research and commercial development network, contributing expertise in tropical animal genetics.

13Nindooinbah
Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Queensland beef breeding property and origin of Nbryo's technology. 15 years of research into embryo transfer and genomics at Nindooinbah under Nick Cameron's management. Euan and Kaye Murdoch's breeding property was the testbed for the platform's development. Commercially focused production of elite genetic progeny continues at Nindooinbah.

nbryo.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1CRV
TypeBroad incumbent
Description

International cattle genetics cooperative with strong dairy and beef breeding programs and embryo services. Comparable to Nbryo as a genetics improvement platform serving commercial and seedstock producers globally.

TypeDirect peer
Description

Global bovine genetics provider with significant IVF/IVP services and sexed semen capabilities. Competes with Nbryo for elite-donor IVF programs and sexed embryo selection in beef and dairy.

TypeDirect peer
Description

Technology-driven bovine IVF company combining reproductive biology with a proprietary data platform to multiply elite genetics, closely aligned with Nbryo's integrated bio-digital platform thesis and donor-centric IVF model.

TypeBroad incumbent
Description

Canadian bovine genetics cooperative offering AI, genomic testing and increasingly IVF/ET services. Comparable as a global genetics improvement company serving dairy and beef customers with an integrated technology stack.

TypeBroad incumbent
Description

Largest global bovine genetics business within Genus plc, with established embryo transfer, sexed semen, and IVF/IVP offerings. Competes across the same customer workflows but at materially greater scale and geographic reach.

TypeDirect peer
Description

Global bovine genetics company where Nbryo CEO Paul Niven previously served as VP of International Sales. Direct comparable in elite dairy and beef genetics, AI services, and increasingly IVP/embryo offerings.

TypeDirect peer
Description

US-based leader in bovine IVF and embryo transfer services, offering OPU, IVP, fresh/frozen embryo transfer and recipient management. Directly comparable to Nbryo's service offering and customer base of seedstock and commercial cattle producers.

TypeBroad incumbent
Description

UK-based bovine genetics business with sexed semen and IVF capabilities serving dairy and beef producers. Comparable as an integrated genetics and embryo services provider targeting commercial herds.

TypeRegional player
Description

Brazil-based bovine IVF and embryo transfer services company. Comparable as a regional IVF/ET services provider focused on tropical cattle production, but operating in Latin America rather than Australia.

TypeBroad incumbent
Description

New Zealand dairy genetics cooperative where Nbryo Director Emma Blott previously held senior executive roles. Comparable as a large-scale, technology-enabled bovine genetics and reproduction services provider, particularly in dairy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nbryo

Livestock Reproductive Biotechnology Servicesnbryo.com

Nbryo is an Australian agri-biotech company commercialising an integrated bovine IVF and embryo transfer platform that enables accelerated, affordable genetic improvement for seedstock, commercial beef, and dairy producers through patented embryo multiplication and bio-digital technologies.

What Nbryo does

Nbryo is an Australian agri-biotech company developing and commercialising an integrated platform for scalable bovine in vitro fertilisation (IVF) and embryo transfer, aimed at cattle seedstock producers, commercial beef operations, and dairy farmers. Founded from 15 years of embryo transfer and genomics research at the Nindooinbah breeding property in Queensland, the company opened its first state-of-the-art Bovine IVF laboratory and headquarters in Eight Mile Plains, Brisbane in October 2023, and has since established two purpose-built Donor Centres in Toogoolawah and Dalby for producers with fewer than 25 donors. The platform combines four integrated steps: genetic selection (including sexing and genomic pre-implantation screening), embryo production via proprietary in vitro production (IVP) culture plus the patented embryo multiplication technology launched in November 2025, a simplified embryo transfer device targeted for October 2026 release, and an AI/ML analytics layer for supply chain forecasting and traceability. Its headline technical claim is condensing seven years of conventional genetic improvement into a seven-day IVP cycle, with multiplication technology delivering twice the embryos using half the donors and half the semen.

The business model combines fee-for-service revenue (OPU, embryo production, fresh and frozen embryo transfer delivered on-farm or via Donor Centres) with unit-priced embryo sales at an introductory AUD $150 per Grade 1 embryo, reduced from AUD $180 following multiplication Stage 1. Go-to-market is sales-led and direct, supported by an in-house field services team, a Tech Ambassador Program of early-adopter reference customers, and an industry partnership with the Australian Wagyu Association. Marketing channels include the proprietary 'Leading the Herd' podcast, an extensive knowledge base, agricultural media coverage, and field-day events. Revenue is not publicly disclosed.

The company is privately held and venture-backed, having raised over AUD $22 million in equity since 2024 across a $10M first close (October 2025) and an $8M second close (March 2026 anchored by USD $4M from the Gates Foundation), plus over AUD $18 million in grant funding from the Gates Foundation, Meat & Livestock Australia, and Australian state and federal programs. Key equity investors include Tenacious Ventures, AgriZeroNZ, Queensland Investment Corporation, Mandalay Venture Partners, and the Murdoch family. Leadership comprises CEO Paul Niven (appointed January 2025), Executive Chairman Dr Gerard Davis, and Co-Founders Euan Murdoch and Nick Cameron, supported by a team of approximately 20 spanning embryology, research, operations, and commercial functions.

Nbryo firmographics

Firmographics
Name
Nbryo
Legal name
Nbryo Pty Limited
Website
https://nbryo.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Nbryo is an Australian agri-biotech company commercialising an integrated bovine IVF and embryo transfer platform that enables accelerated, affordable genetic improvement for seedstock, commercial beef, and dairy producers through patented embryo multiplication and bio-digital technologies.
Ownership category
akta.pro rank

Nbryo industry classification

Industry
Product category
Livestock Reproductive Biotechnology Services
NAICS
Support Activities for Animal Production (11521)
SIC
Agricultural Services (700), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYAFACAEAB
Embryo Transfer (ET) & IVF Services (Superovulation, Flushing, Implantation)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Livestock Services (Breeding, AI, Pregnancy Checking, Handling)
SECONDARYAFACAEAD
Breeding Program Design & Genetic Consulting (Mating Plans, EPD/Index Selection)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Livestock Services (Breeding, AI, Pregnancy Checking, Handling)

Keywords

  • Bovine IVF services
  • Embryo transfer technology
  • Livestock genetic improvement
  • Cattle breeding biotechnology
  • Animal reproductive services

Where Nbryo is headquartered

Location

Headquarters

HQ city
Eight Mile Plains
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Nbryo business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. IVF and Embryo Transfer Services: Nbryo provides commercial in vitro fertilisation (IVF) and embryo transfer (ET) services to cattle producers. Oocyte collection (OPU), embryo production, fresh or frozen embryo transfer, and associated laboratory services are offered as fee-for-service programs. Services are delivered on-farm or at Nbryo's Donor Centres.
  2. Embryo Sales (Grade 1 Embryos): Nbryo produces and sells Grade 1 embryos at AUD $150 (introductory price, reduced from $180). Embryo multiplication technology enables higher embryo yields, reducing cost per embryo. Future genomic screening will allow selection of embryos with specific traits before transfer.
  3. Equity Capital Raising: Nbryo has raised over AUD $22 million in equity since 2024, including a $10 million first close (October 2025) and an $8 million second close (March 2026). The Gates Foundation contributed USD $4 million. SAFE note conversion of $12.3 million brought total raised since 2024 to over $22 million. Additionally, over $18 million in grant funding has been received from Gates Foundation, Meat & Livestock Australia, and government programs.
  4. Equity Investment (Seed Round): Nbryo has an open Seed Round for new equity investors, managed by Investor Relations contact Nick Bonifant. The company is raising capital to fund technology development, commercial expansion, and the October 2026 product launch.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGrade 1 Embryo — Introductory Price
Unit PricingPay-as-you-goDonor Centre IVF Programs
Unit PricingPay-as-you-goOocyte Collection (OPU) Services
Unit PricingPay-as-you-goEmbryo Transfer Services

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Nbryo product offering

Product offering

Core offering

Nbryo provides commercial bovine in vitro fertilisation (IVF), ovum pick-up (OPU), and embryo transfer (ET) services to cattle producers, producing and selling Grade 1 embryos at AUD $150 per unit. The offering is anchored by a patented Embryo Multiplication Technology that doubles embryo yield while improving Embryo Development Rates, and is delivered through on-farm field services, two purpose-built Donor Centres in Queensland, and a development pipeline that includes genomic pre-implantation screening, a proprietary embryo transfer device, and AI/ML-enabled herd analytics.

Product overview

Nbryo is developing and commercialising an integrated technology platform for bovine IVF that enables accessible, accelerated, and affordable genetic improvement through in vitro production of embryos. The platform combines eight key services across the reproductive technology workflow: Breeding Objective Design (in development), Oocyte Collection Services, Embryo Production, Genomic Screening (coming soon), Embryo Multiplication Technology (launched November 2025), Embryo Preservation (in development), Embryo Transfer Technology with a device planned for October 2026 release, and Analysis/Data Services. Using advanced bio-digital and robotic technologies, the platform enables 7 years of genetic improvement to be achieved within a 7-day in vitro embryo production cycle. Nbryo also operates Donor Centre facilities in Toogoolawah and Dalby, Queensland.

Differentiator

Problem solved

Functional benefit

Products and services

  • Commercial IVF and Embryo Transfer Services Fee-for-service commercial bovine IVF program delivered through Nbryo's field services team and laboratory. Includes ovum pick-up (OPU) on-farm or at collection centres, fertilisation and embryo culture in the lab, and fresh or frozen embryo transfer using fixed-time embryo transfer (FTET) protocols. Optional FSH stimulation is available to increase oocyte quality and Embryo Development Rates. OPU can be performed as frequently as fortnightly. Services are delivered on-farm for larger producers and via Donor Centres for those with fewer than 25 donors.
  • Nbryo Donor Centres Two purpose-built facilities in Toogoolawah and Dalby, Queensland, that provide structured, donor-focused IVF programs integrating donor management, OPU, fertilisation, embryo culture, and transfer planning. Designed for producers with fewer than 25 donors who cannot achieve economies of scale with on-farm infrastructure, making advanced reproductive technology accessible, practical, and affordable.
  • Embryo Multiplication Technology A patented biological process that naturally multiplies embryo yield while improving Embryo Development Rates. Not cloning or embryo splitting, the technology produces more Grade 1 embryos at lower cost. Enabled Grade 1 embryo introductory pricing of AUD $150 (reduced from AUD $180), with further cost reductions expected as the platform scales.
  • Embryo Transfer Device A proprietary device under development that will enable semi-skilled operators such as AI technicians to perform embryo transfers into recipient cows without requiring a specialist ET vet or epidural. Designed to lower skill barriers, reduce cost, and address the critical shortage of skilled embryo transfer technicians in the cattle industry.
  • Genomic Pre-implantation Screening Technology to select or de-select embryos in the dish based on genomic traits including gender, horn/poll status, recessive genetic conditions, coat colour, and performance-oriented SNP panels. Enables selection of embryos before implantation rather than waiting for calf birth to assess traits, supporting faster structural herd change and direct selection for methane reduction, productivity, and welfare traits.
  • Grade 1 Embryos Nbryo produces and sells Grade 1 embryos at an introductory price of AUD $150 per embryo, reduced from AUD $180 through Stage 1 of embryo multiplication technology. Embryo multiplication enables higher yields and lower per-embryo cost. Future genomic screening will allow selection of embryos with specific traits before transfer.

Quantifiable outcome

  • 7 years of genetic improvement achievable in a 7-day in vitro embryo production cycle, compared to existing systems that achieve 10% trait improvement over 7 years at best
  • +5 more outcomes

Companies that use Nbryo

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Nbryo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Nbryo partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered key, research, strategic, pilot and foundational.

  • Australian Wagyu Association (AWA)keyStrategic or Co-development Partner · 1 March 2024Corporate business partnership recognising alignment between Nbryo and AWA in advancing the Australian livestock industry. Partnership provides market access and co-marketing opportunities within the Australian Wagyu breeder community. AWA members benefit from preferential access to Nbryo's IVF services and technology platform.
  • University of SydneyresearchStrategic or Co-development PartnerResearch partner contributing scientific expertise. Associate Professor Margot Day serves as Nbryo's Lead Scientist from the University of Sydney, playing a key role in developing the embryo multiplication technology.
  • University of Queensland (UQ)researchStrategic or Co-development PartnerResearch partner from the Nbryo/Nindooinbah program origins. Euan Murdoch served as Adjunct Professor at UQ's Australian Institute of Bioengineering and Nanotechnology and member of UQ's Institute of Molecular Biosciences Commercialisation Board.
  • RMIT UniversityresearchStrategic or Co-development PartnerResearch partner in Nbryo's multi-disciplinary product development network spanning biology, genomics, engineering, biosensors, and data science. Research partner Crispin from RMIT is referenced in team activities.
  • University of MichiganresearchStrategic or Co-development PartnerInternational research partner in Nbryo's network across Australia, New Zealand, India, Kenya, and the USA.
  • International Livestock Research Institute (ILRI)strategicStrategic or Co-development PartnerILRI Director General Professor Appolinaire Djikeng serves on Nbryo's Scientific Advisory Committee. ILRI focuses on challenges facing smallholder production systems in Sub-Saharan Africa, where Nbryo plans to deploy its platform to address food security and climate challenges. Collaboration helps plan Nbryo platform development for developing country contexts.
  • Jemalong Pastoral CompanypilotGTM or Marketing PartnerQueensland Wagyu operation participating in Nbryo's Tech Ambassador Program as an early adopter of Nbryo's IVF technology. The Bachmann family (Maree and Russell) completed two OPU sessions producing 62 embryos implanted into recipients. They serve as reference customers and advocates, providing feedback on early-stage technology.
  • In2BeingresearchTechnology or IntegrationPartner company in Nbryo's research network contributing to platform development.
  • Expedite Animal HealthresearchTechnology or IntegrationPartner company in Nbryo's research network contributing to the development of reproductive biotechnology.
  • Global Health Labs (GHLabs)researchStrategic or Co-development PartnerPartner institution in Nbryo's international research network contributing to platform development for livestock genetic improvement.
  • New Zealand Agricultural Greenhouse Gas Research CentreresearchStrategic or Co-development PartnerPartner organisation in Nbryo's research network with focus on agricultural greenhouse gas mitigation, directly aligned with Nbryo's methane reduction technology goals.
  • Tropical Animal Genetics (TAG)researchTechnology or IntegrationPartner company in Nbryo's research and commercial development network, contributing expertise in tropical animal genetics.
  • NindooinbahfoundationalStrategic or Co-development PartnerQueensland beef breeding property and origin of Nbryo's technology. 15 years of research into embryo transfer and genomics at Nindooinbah under Nick Cameron's management. Euan and Kaye Murdoch's breeding property was the testbed for the platform's development. Commercially focused production of elite genetic progeny continues at Nindooinbah.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Nbryo competitors and assessment

Company assessment

Broad incumbents

  • CRV: International cattle genetics cooperative with strong dairy and beef breeding programs and embryo services. Comparable to Nbryo as a genetics improvement platform serving commercial and seedstock producers globally.
  • Semex: Canadian bovine genetics cooperative offering AI, genomic testing and increasingly IVF/ET services. Comparable as a global genetics improvement company serving dairy and beef customers with an integrated technology stack.
  • ABS Global (Genus plc): Largest global bovine genetics business within Genus plc, with established embryo transfer, sexed semen, and IVF/IVP offerings. Competes across the same customer workflows but at materially greater scale and geographic reach.
  • Cogent Breeding: UK-based bovine genetics business with sexed semen and IVF capabilities serving dairy and beef producers. Comparable as an integrated genetics and embryo services provider targeting commercial herds.
  • Livestock Improvement Corporation (LIC): New Zealand dairy genetics cooperative where Nbryo Director Emma Blott previously held senior executive roles. Comparable as a large-scale, technology-enabled bovine genetics and reproduction services provider, particularly in dairy.

Direct peers

  • ST Genetics: Global bovine genetics provider with significant IVF/IVP services and sexed semen capabilities. Competes with Nbryo for elite-donor IVF programs and sexed embryo selection in beef and dairy.
  • Vytelle: Technology-driven bovine IVF company combining reproductive biology with a proprietary data platform to multiply elite genetics, closely aligned with Nbryo's integrated bio-digital platform thesis and donor-centric IVF model.
  • Alta Genetics: Global bovine genetics company where Nbryo CEO Paul Niven previously served as VP of International Sales. Direct comparable in elite dairy and beef genetics, AI services, and increasingly IVP/embryo offerings.
  • Trans Ova Genetics: US-based leader in bovine IVF and embryo transfer services, offering OPU, IVP, fresh/frozen embryo transfer and recipient management. Directly comparable to Nbryo's service offering and customer base of seedstock and commercial cattle producers.

Regional players

  • InVitro Brazil: Brazil-based bovine IVF and embryo transfer services company. Comparable as a regional IVF/ET services provider focused on tropical cattle production, but operating in Latin America rather than Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nbryo social profiles

Digital presence

Nbryo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nbryo leadership team

Management profile

Number of profiles

Profiles10 records

Nbryo funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nbryo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nbryo

What does Nbryo do?

Nbryo provides commercial bovine in vitro fertilisation (IVF), ovum pick-up (OPU), and embryo transfer (ET) services to cattle producers, producing and selling Grade 1 embryos at AUD $150 per unit. The offering is anchored by a patented Embryo Multiplication Technology that doubles embryo yield while improving Embryo Development Rates, and is delivered through on-farm field services, two purpose-built Donor Centres in Queensland, and a development pipeline that includes genomic pre-implantation screening, a proprietary embryo transfer device, and AI/ML-enabled herd analytics.

Is Nbryo a public or private company?

Nbryo is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nbryo founded?

Nbryo was founded in 2023. It employs 11 to 50 people.

Where is Nbryo based?

Nbryo is headquartered in Eight Mile Plains, Australia, in the Oceania region.

How does Nbryo make money?

Four revenue lines are on record. IVF and Embryo Transfer Services are the primary driver. The others are embryo Sales (Grade 1 Embryos), equity Capital Raising and equity Investment (Seed Round).

Who are Nbryo's main competitors?

Broad incumbents on record are CRV, Semex, ABS Global (Genus plc), Cogent Breeding and Livestock Improvement Corporation (LIC). Direct peers are ST Genetics, Vytelle, Alta Genetics and Trans Ova Genetics. InVitro Brazil is listed as a regional player.

Does Nbryo have an API?

No public API is recorded for Nbryo.

What industry is Nbryo in?

Nbryo's product category is Livestock Reproductive Biotechnology Services. Its primary akta.pro industry code is AFACAEAB, Embryo Transfer (ET) & IVF Services (Superovulation, Flushing, Implantation), with a secondary code of AFACAEAD, Breeding Program Design & Genetic Consulting (Mating Plans, EPD/Index Selection). Its NAICS code is 11521 and its SIC code is 700.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SmartCompanySeven ANZ startups that raised $111.5 million this weekSeven startups from Australia and New Zealand collectively raised $111.5 million in funding this week across sectors including fintech, marine tech, agtech, AI, and defense. The largest round was $62.5 million for Australian fintech Constantinople, followed by $27 million for New Zealand marine technology firm Vessev. Other funded companies include Nbryo, Sophiie.ai, Seitec, Bower, and Visaible.ai.NbryoQueensland Minister for Primary Industries Visits Nbryo committing to a $2 million investmentQueensland Minister Tony Perrett visited Nbryo's Brisbane laboratory, touring embryo development and assessment processes. The visit coincides with a $2 million investment in Nbryo through the QIC Sowing the Seeds fund, aimed at advancing bovine reproductive technologies.Mirage NewsTech Boosts for Queensland Cattle, Dairy ProducersQueensland-based agricultural biotechnology company Nbryo has received a $2 million investment from the Queensland Government's Sowing the Seeds of Farming Innovation Fund. The funding, managed by the Queensland Investment Corporation (QIC), will accelerate Nbryo's technology to reduce cattle breeding time from seven years to seven days, aiming to improve productivity for beef and dairy producers.NbryoAgri-biotech company announces second close of capital raiseNbryo announced a second capital close of AUD$8 million, bringing total raised to AUD$18 million. The company is developing bovine reproductive technologies, with support from Tenacious Ventures, AgriZeroNZ, and a new Gates Foundation equity investment.StatementsQueensland startup Nbryo secures $10 million global backing to transform cattle breedingQueensland-based AgTech startup Nbryo has secured $10 million in global funding to scale its in vitro embryo production technology, which significantly accelerates cattle breeding processes. The investment round includes capital from investors such as QIC, Tenacious Ventures, Mandalay Ventures, and AgriZero, with technical collaboration from the Gates Foundation. This funding allows Nbryo to expand operations and commercialize its platform to improve efficiency and sustainability in the global beef and dairy industries.SmartCompanyQueensland agtech Nbryo raises $10 million to rewrite the future of livestock breedingQueensland-based agri-biotech company Nbryo has raised $10 million in funding to develop a bovine IVF platform for cattle producers. The company aims to deliver scalable, high-quality breeding outcomes to the global livestock market. Nbryo CEO Paul Niven leads the startup focused on reproductive technology for cattle.NbryoNbryo completes AUD $10 Million Capital Raising to Accelerate Genetic Improvement in Beef & DairyAustralian agtech company Nbryo has completed a AUD $10 million capital raising co-led by existing investor Tenacious Ventures and new investor AgriZeroNZ, with Queensland Investment Corporation also joining as a new investor. The raise triggered conversion of $12.3 million in SAFE notes, bringing total funds raised since 2024 to more than $22 million, in addition to over $18 million in grant funding received from the Gates Foundation, Meat and Livestock Australia, and government programs. The capital will accelerate Nbryo's proprietary IVF platform for cattle reproduction, expand commercial IVF services in the Australian cattle industry, and support the launch of embryo multiplication technology in late 2025 and an embryo transfer device planned for market release in October 2026.